SGLT-2 Therapy Center

The FDA has given a Fast Track Designation to accelerate study of Farxiga’s effect on reduction in mortality and heart failure after a heart attack.

Our chart can help you choose the best SGLT-2 inhibitor for your particular patient.

Download the SGLT-2 inhibitors chart (PDF format)

The future could hold more treatment options for patients with type 1 diabetes. 

Could empagliflozin contribute to the early treatment of NAFLD in patients with T2DM? 

SGLT2 Inhibitors and their use for preventing cardiovascular diseases. 

SGLT-2 inhibitors have proved to be successful hypoglycemics, so should they be recommended earlier for those not achieving goal A1c reductions? 

A female patient, 42 years of age, with type 2 diabetes, is overweight with a history of vaginal yeast infections with elevated glucose levels. Wanting to better manage her diabetes and lose some weight, the commercials about SGLT-2 inhibitors caught her attention.

More may be better unless it involves tablets. A newly approved, more straightforward way to treat type 2 diabetes.

The use of SGLT2 inhibitors was associated with reduced risk of any cause of death in patients with or without a history of major cardiovascular disease.

Examining both the clinical and the cost outcomes for patients with type 2 diabetes with established cardiovascular disease.